14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today COLL ranks #11946 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$17.82 (-3.88%)

Volume: 103k

Closed: Jan 18, 2022

Hollow Logo Score: -3.272

Collegium Pharmaceutical Stock Forecast

$17.82 (-3.88%)

Volume: 103k

Closed: Jan 18, 2022

Score Hollow Logo -3.272

Collegium Pharmaceutical Company Profile

780 Dedham Street

Canton MA 02021




Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an oral formulation of oxycodone. The company is also developing COL-195, a hydrocodone for the treatment of chronic pain; COL-172, an oxymorphone for the treatment of chronic pain; COL-196, a morphine formulation to treat pain; and COL-171, a proprietary preclinical DETERx methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE